BACKGROUND: Poststenting ischemic events occur despite dual-antiplatelet therapy, suggesting that a "one size fits all" antithrombotic strategy has significant limitations. Ex vivo platelet function measurements may facilitate risk stratification and personalized antiplatelet therapy. METHODS: We investigated the prognostic utility of the strength of adenosine diphosphate (ADP)-induced (MA(ADP)) and thrombin-induced (MA(THROMBIN)) platelet-fibrin clots measured by thrombelastography and ADP-induced light transmittance aggregation (LTA(ADP)) in 225 serial patients after elective stenting treated with aspirin and clopidogrel. Ischemic and bleeding events were assessed over 3 years. RESULTS: Overall, 59 (26%) first ischemic events occurred. Patients with ischemic events had higher MA(ADP), MA(THROMBIN), and LTA(ADP) (P < .0001 for all comparisons). By receiver operating characteristic curve analysis, MA(ADP) >47 mm had the best predictive value of long-term ischemic events compared with other measurements (P < .0001), with an area under the curve = 0.84 (95% CI 0.78-0.89, P < .0001). The univariate Cox proportional hazards model identified MA(ADP) >47 mm, MA(THROMBIN) >69 mm, and LTA(ADP) >34% as significant independent predictors of first ischemic events at the 3-year time point, with hazard ratios of 10.3 (P < .0001), 3.8 (P < .0001), and 4.8 (P < .0001), respectively. Fifteen bleeding events occurred. Receiver operating characteristic curve and quartile analysis suggests MA(ADP) <or=31 as a predictive value for bleeding. CONCLUSION: This study is the first demonstration of the prognostic utility of MA(ADP) in predicting long-term event occurrence after stenting. The quantitative assessment of ADP-stimulated platelet-fibrin clot strength measured by thrombelastography can serve as a future tool in investigations of personalized antiplatelet treatment designed to reduce ischemic events and bleeding. Copyright 2010 Mosby, Inc. All rights reserved.
BACKGROUND: Poststenting ischemic events occur despite dual-antiplatelet therapy, suggesting that a "one size fits all" antithrombotic strategy has significant limitations. Ex vivo platelet function measurements may facilitate risk stratification and personalized antiplatelet therapy. METHODS: We investigated the prognostic utility of the strength of adenosine diphosphate (ADP)-induced (MA(ADP)) and thrombin-induced (MA(THROMBIN)) platelet-fibrin clots measured by thrombelastography and ADP-induced light transmittance aggregation (LTA(ADP)) in 225 serial patients after elective stenting treated with aspirin and clopidogrel. Ischemic and bleeding events were assessed over 3 years. RESULTS: Overall, 59 (26%) first ischemic events occurred. Patients with ischemic events had higher MA(ADP), MA(THROMBIN), and LTA(ADP) (P < .0001 for all comparisons). By receiver operating characteristic curve analysis, MA(ADP) >47 mm had the best predictive value of long-term ischemic events compared with other measurements (P < .0001), with an area under the curve = 0.84 (95% CI 0.78-0.89, P < .0001). The univariate Cox proportional hazards model identified MA(ADP) >47 mm, MA(THROMBIN) >69 mm, and LTA(ADP) >34% as significant independent predictors of first ischemic events at the 3-year time point, with hazard ratios of 10.3 (P < .0001), 3.8 (P < .0001), and 4.8 (P < .0001), respectively. Fifteen bleeding events occurred. Receiver operating characteristic curve and quartile analysis suggests MA(ADP) <or=31 as a predictive value for bleeding. CONCLUSION: This study is the first demonstration of the prognostic utility of MA(ADP) in predicting long-term event occurrence after stenting. The quantitative assessment of ADP-stimulated platelet-fibrin clot strength measured by thrombelastography can serve as a future tool in investigations of personalized antiplatelet treatment designed to reduce ischemic events and bleeding. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: E M Antman; M Cohen; P J Bernink; C H McCabe; T Horacek; G Papuchis; B Mautner; R Corbalan; D Radley; E Braunwald Journal: JAMA Date: 2000-08-16 Impact factor: 56.272
Authors: Nicoline J Breet; Jochem W van Werkum; Heleen J Bouman; Johannes C Kelder; Henk J T Ruven; Egbert T Bal; Vera H Deneer; Ankie M Harmsze; Jan A S van der Heyden; Benno J W M Rensing; Maarten J Suttorp; Christian M Hackeng; Jurriën M ten Berg Journal: JAMA Date: 2010-02-24 Impact factor: 56.272
Authors: Paul A Gurbel; Kevin P Bliden; Kirk Guyer; Peter W Cho; Kazi A Zaman; Rolf P Kreutz; Ashwani K Bassi; Udaya S Tantry Journal: J Am Coll Cardiol Date: 2005-10-21 Impact factor: 24.094
Authors: Kevin P Bliden; Joseph DiChiara; Udaya S Tantry; Ashwani K Bassi; Srivasavi K Chaganti; Paul A Gurbel Journal: J Am Coll Cardiol Date: 2007-01-26 Impact factor: 24.094
Authors: Paul A Gurbel; Mark J Antonino; Kevin P Bliden; Joseph Dichiara; Thomas A Suarez; Anand Singla; Udaya S Tantry Journal: Platelets Date: 2008-12 Impact factor: 3.862
Authors: Gailing Chen; Kevin P Bliden; Rahul Chaudhary; Fang Liu; Himabindu Kaza; Eliano P Navarese; Udaya S Tantry; Paul A Gurbel Journal: J Thromb Thrombolysis Date: 2017-08 Impact factor: 2.300
Authors: Rahul Chaudhary; Kevin P Bliden; Udaya S Tantry; Nafees Mohammed; Denny Mathew; Martin G Gesheff; Christopher J Franzese; Paul A Gurbel Journal: J Thromb Thrombolysis Date: 2016-04 Impact factor: 2.300
Authors: Kevin P Bliden; Rahul Chaudhary; Nafees Mohammed; Adina A Muresan; Carlos G Lopez-Espina; Eli Cohen; Gabriel Raviv; Marc Doubleday; Fowzia Zaman; Blessy Mathew; Udaya S Tantry; Paul A Gurbel Journal: J Thromb Thrombolysis Date: 2017-05 Impact factor: 2.300
Authors: Rolf P Kreutz; Janelle Owens; Jeffrey A Breall; Deshun Lu; Elisabeth von der Lohe; Islam Bolad; Anjan Sinha; David A Flockhart Journal: Blood Coagul Fibrinolysis Date: 2013-04 Impact factor: 1.276